Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38.3M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
24.9M
-
Shares change
-
+24.2M
-
Total reported value, excl. options
-
$425M
-
Value change
-
+$414M
-
Number of buys
-
44
-
Price
-
$17.12
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q4 2021
45 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.9M shares
of 38.3M outstanding shares and own 64.83% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.7M shares), MPM ASSET MANAGEMENT LLC (4.43M shares), 5AM Venture Management, LLC (4.41M shares), WELLINGTON MANAGEMENT GROUP LLP (3.11M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.02M shares), Redmile Group, LLC (1.95M shares), StepStone Group LP (761K shares), TCG Crossover Management, LLC (664K shares), GOLDMAN SACHS GROUP INC (445K shares), and BlackRock Inc. (444K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.